Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) closed at $21.76 in the last session, down -2.07% from day before closing price of $22.22. In other words, the price has decreased by -$2.07 from its previous closing price. On the day, 0.9 million shares were traded. ARWR stock price reached its highest trading level at $22.53 during the session, while it also had its lowest trading level at $21.45.
Ratios:
We take a closer look at ARWR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.65 and its Current Ratio is at 4.65. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 02 ’24 when Oliver Tracie sold 9,394 shares for $25.28 per share. The transaction valued at 237,480 led to the insider holds 127,107 shares of the business.
Vakiener Victoria sold 1,799 shares of ARWR for $41,935 on May 02 ’24. The Director now owns 30,205 shares after completing the transaction at $23.31 per share. On Apr 01 ’24, another insider, Hamilton James C, who serves as the Chief Discovery/Trans Medicine of the company, sold 6,000 shares for $28.03 each. As a result, the insider received 168,180 and left with 204,851 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 2705094400 and an Enterprise Value of 2733180416. For the stock, the TTM Price-to-Sale (P/S) ratio is 137.66 while its Price-to-Book (P/B) ratio in mrq is 8.18. Its current Enterprise Value per Revenue stands at 139.107 whereas that against EBITDA is -5.159.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $39.83, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is -15.42%, while the 200-Day Moving Average is calculated to be -20.90%.
Shares Statistics:
According to the various share statistics, ARWR traded on average about 1.02M shares per day over the past 3-months and 869070 shares per day over the past 10 days. A total of 124.31M shares are outstanding, with a floating share count of 118.49M. Insiders hold about 4.68% of the company’s shares, while institutions hold 79.05% stake in the company. Shares short for ARWR as of 1723680000 were 10450472 with a Short Ratio of 10.26, compared to 1721001600 on 9044745. Therefore, it implies a Short% of Shares Outstanding of 10450472 and a Short% of Float of 9.86.
